Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells

Biological Chemistry

Volumn 389, Issue 1, 2008, Pages 57-67

  Donninger, Howard ^a   Binder, Anke ^a   Bohm, Lothar ^b   Parker, M Iqbal ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Breast cancer; Cell cycle; Chemotherapeutic agents

Indexed keywords

CISPLATIN; COBALT 60; DAUNORUBICIN; MELPHALAN; PROTEIN P53;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER PATIENT; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL STRAIN 3T3; COLONY FORMATION; CONTROLLED STUDY; GENE MUTATION; GROWTH INHIBITION; IRRADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CISPLATIN; DAUNORUBICIN; DNA, COMPLEMENTARY; IMMUNOHISTOCHEMISTRY; KINETICS; MELPHALAN; MICE; MODELS, MOLECULAR; MUTATION; NIH 3T3 CELLS; PROTEIN CONFORMATION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 37349124730     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2008.010     Document Type: Article

References (80)

1. 2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA 92, 8493-8497.
2. Almasan, A., Linke, S.P., Paulson, T.G., and Wahl, G.M. (1995). Genetic instability as a consequence of inappropriate entry into and progression through S-phase. Cancer Metastas. Rev. 14, 59-73.
3. Baker, S.J., Markowitz, S., Fearon, E.R., Willson, J.K.V., and Vogelstein, B. (1990). Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249, 912-915.
4. Bensaad, K., Le, B.M., Unsal, K., Strano, S., Blandino, G., Tominaga, O., Rouillard, D., and Soussi, T. (2003). Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73. J. Biol. Chem. 278, 10546-10555.
5. Berns, E.M., Foekens, J.A., Vossen, R., Look, M.P., Devilee, P., Henzen-Logmans, S.C., van Staveren, I.L., van Putten, W.L., Inganäs, M., Meijer-van Gelser, M.E., et al. (2000). Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res. 60, 2155-2162.
6. Binder, A., Theron, T., Donninger, H., Parker, M., and Bohm, L. (2002). Radiosensitization and DNA repair inhibition by pentoxifylline in NIH3T3 p53 transfectants. Int. J. Radiat. Biol. 78, 991-1000.
7. Blandino, G., Levine, A.J., and Oren, M. (1999). Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18, 477-485.
8. Buganim, Y., Kalo, E., Brosh, R., Besserglick, H., Nachmany, I., Rais, Y., Stambolsky, P., Tang, X., Milyavsky, M., Shats, I., et al. (2006). Mutant p53 protects cells from 12-O-tetrandecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction. Cancer Res. 66, 10750-10759.
9. Cao, Y., Gao, Q., Wazer, D.E., and Band, V. (1997). Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells. Cancer Res. 57, 5584-5589.
10. Chang, F.L. and Lai, M.D. (2001). Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells. J. Urol. 166, 304-310.
11. Chen, C. and Okayama, H. (1988). Calcium phosphate-mediated gene transfer. A highly efficient system for stably transforming cells with plasmid DNA. Biotechniques 6, 632-638.
12. Chen, Y.J., Hakin-Smith, V., Teo, M., Xinarianos, G.E., Jellinek, D.A., Carroll, T., McDowell, D., MacFarlane, M.R., Boet, R., Baguley, B.C., et al. (2006). Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res. 66, 6473-6476.
13. Chene, P. (1998). In vitro analysis of the dominant negative effect of p53 mutants. J. Mol. Biol. 281, 205-209.
14. Cheng, J. and Baldi, P. (2006). A machine learning information retrieval approach to protein fold recognition. Bioinformatics 22, 1456-1463.
15. Cho, Y., Gorina, S., Jeffrey, P.D., and Pavletich, N.P. (1994). Crystal structure of a p53 tumour suppressor-DNA complex: understanding tumourigenic mutations. Science 265, 346-355.
16. Clarke, A.R., Purdie, C.A., Harrison, D.J., Morris, R.G., Bird, C.C., Hooper, M.L., and Wyllie, A.H. (1993). Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852.
17. DeGregori, J., Leone, G., Ohtani, K., Miron, A., and Nevins, J.R. (1995). E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev. 9, 2873-2887.
18. Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., and Piaggio, G. (2006). Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10, 191-202.
19. Diccianni, M.B., Hsiao, M., Mukherjee, S., Shao, L.-E., and Yu, A.L. (1994). Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 84, 3105-3112.
20. Diller, L., Kassel, J., Nelson, C.E., Gryka, M.A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S.J., Vogelstein, B., et al. (1990). p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol. 10, 5772-5781.
21. Domagala, W., Harezga, B., Szadowska, A., Markiewski, M., Weber, K., and Osborn, M. (1993). Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. Am. J. Pathol. 142, 669-674.
22. Donninger, H., Dent, D.M., and Parker, M.I. (2003). Infrequent and unusual p53 mutations in breast cancers in South Africa. Genome Lett. 4, 157-164.
23. Dumenco, L., Oguey, D., Wu, J., Messier, N., and Fausto, N. (1995). Introduction of a murine p53 mutation corresponding to human codon 249 into a murine hepatocyte cell line results in growth advantage, but not in transformation. Hepatology 22, 1279-1288.
24. el-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumour suppression. Cell 75, 817-825.
25. el-Deiry, W.S., Harper, J.W., O'Connor, P.M., Velculescu, V.E., Canman, C.E., Jackman, J., Pietenpol, J.A., Burrell, M., Hill, D.E., Wang, Y., et al. (1994). WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54, 1169-1174.
26. Farber, E. (1984). The multistep nature of cancer development. Cancer Res. 44, 4217-4223.
27. Flamini, G., Curigliano, G., Ratto, C., Astone, A., Ferretti, G., Nucera, P., Sofa, L., Sgambato, A., Boninsegna, A., Crucitti, F., et al. (1996). Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. Eur. J. Cancer 32A, 802-806.
28. Friedlander, P., Haupt, Y., Prives, C., and Oren, M. (1996). A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol. 16, 4961-4971.
29. Fushimi, K., Iijima, M., Gao, C., Kondo, T., Tsuji, T., Hashimoto, T., Mihara, K., and Namba, M. (1997). Transformation of normal human fibroblasts into immortalized cells with the mutated p53 gene and X-rays. Int. J. Cancer 70, 135-140.
30. Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., and Prives, C. (2001). A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21, 1874-1887.
31. Gao, Q., Hauser, S.H., Liu, X.L., Wazer, D.E., Madoc-Jones, H., and Band, V. (1996). Mutant p53-induced immortalization of primary human mammary epithelial cells. Cancer Res. 56, 3129-3133.
32. Geisler, S., Lønning, P.E., Aas, T., Johnsen, H., Fluge, Ø., Haugen, D.F., Lillehaug, J.R., Akslen, L.A., and Børreson- Dale, A.-L. (2001). Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61, 2505-2512.
33. Gerwin, B.I., Spillare, E., Forrester, K., Lehman, T.A., Kispert, J., Welsh, J.A., Pfeifer, A.M., Lechner, J.F., Baker, S.J., Vogelstein, B., et al. (1992). Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. Proc. Natl. Acad. Sci. USA 89, 2759-2763.
34. Gualberto, A., Aldape, K., Kozakiewicz, K., and Tlsty, T.D. (1998). An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc. Natl. Acad. Sci. USA 95, 5166-5171.
35. Harris, C.C. (1996). Structure and function of the p53 tumour suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88, 1442-1455.
36. Ichikawa, A., Kinoshita, T., Watanabe, T., Kato, H., Nagai, H., Tsushita, K., Saito, H., and Hotta, T. (1997). Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N. Engl. J. Med. 337, 529-534.
37. Ishioka, C., Shimodaira, H., Englert, C., Shimada, A., Osada, M., Jia, L.Q., Suzuki, T., Gamo, M., and Kanamaru, R. (1997). Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells. Biochem. Biophys. Res. Commun. 232, 54-60.
38. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R.W. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311.
39. Kern, S.E., Pietenpol, J.A., Thiagalingam, S., Seymour, A., Kinzler, K.W., and Vogelstein, B. (1992). Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-830.
40. Kikuchi-Yanoshita, R., Tanaka, K., Muraoka, M., Konishi, M., Kawashima, I., Takamoto, S., Hirai, H., and Miyaki, M. (1995). Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene. Oncogene 11, 1339-1345.
41. Kohli, R.M. (1998). Site-directed mutagenesis using PCR-mediated introduction of silent mutations. Biotechniques 25, 184-188.
42. Kuerbitz, S.J., Plunkett, B.S., Walsh, W.V., and Kastan, M.B. (1992). Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89, 7491-7495.
43. Lane, D.P. (1992). p53, guardian of the genome. Nature 358, 15-16.
44. Lang, G.A., Iwakuma, T., Suh, Y.A., Liu, G., Rao, V.A., Parant, J.M., Valentin-Vega, Y.A., Terzian, T., Caldwell, L.C., Strong, L.C., et al. (2004). Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861-872.
45. Li, R., Sutphin, P.D., Schwartz, D., Matas, D., Almog, N., Wolkowicz, R., Goldfinger, N., Pei, H., Prokocimer, M., and Rotter, V. (1998). Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 16, 3269-3277.
46. Lim, Y.P., Lim, T.T., Chan, Y.L., Song, A.C., Yeo, B.H., Vojtesek, B., Coomber, D., Rajagopal, G., and Lane, D. (2007). The p53 knowledgebase: an integrated information resource for p53 research. Oncogene 26, 1517-1521.
47. Lin, D., Shields, M.T., Ullrich, S.J., Appella, E., and Mercer, W.E. (1992). Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in the late G1 phase. Proc. Natl. Acad. Sci. USA 89, 9210-9214.
48. Lin, X., Ramamurthi, K., Mishima, M., Kondo, A., Christen, R.D., and Howell, S.B. (2001). p53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res. 61, 1508-1516.
49. Livingstone, L.R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T.D. (1992). Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70, 923-935.
50. Lowe, S.W., Ruley, H.E., Jacks, T., and Housman, D.E. (1993a). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967.
51. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A., and Jacks, T. (1993b). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849.
52. Lowe, S.W., Bodis, S., McClatchey, A., Remington, L., Ruley, H.E., Fisher, D.E., Housman, D.E., and Jacks, T. (1994). p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810.
53. Ludwig, R.L., Bates, S., and Vousden, K.H. (1996). Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol. 16, 4952-4960.
54. McCracken, A.A., Kruse, K.B., and Brown, J.L. (1988). An enrichment selection for mutants resulting from oligonucleotide-directed mutagenesis of double-stranded DNA. Biotechniques 6, 332-339.
55. Mizuarai, S., Yamanaka, K., and Kotani, H. (2006). Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res. 66, 6319-6326.
56. Moll, U.M., Riou, G., and Levine, A.J. (1992). Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA 89, 7262-7266.
57. O'Farrell, T.J., Ghosh, P., Dobashi, N., Sasaki, C.Y., and Longo, D.L. (2004). Comparison of the effect of mutant and wild-type p53 on global gene expression. Cancer Res. 64, 8199-8207.
58. Olive, K.P., Tuveson, D.A., Ruhe, Z.C., Yin, B., Willis, N.A., Bronson, R.T., Crowley, D., and Jacks, T. (2004). Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860.
59. Olivier, M., Eeles, R., Hollstein, M., Khan, M.A., Harris, C.C., and Hainaut, P. (2002). The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19, 607-614.
60. Peart, M.J. and Prives, C. (2006). Mutant p53 gain of function: the NF-Y connection. Cancer Cell 10, 173-174.
61. Perryman, L.A., Blair, J.M., Kingsley, E.A., Szymanska, B., Ow, K.T., Wen, V.W., MacKenzie, K.L., Vermeulen, P.B., Jackson, P., and Russell, P.J. (2006). Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo. Biochem. Biophys. Res. Commun. 345, 1207-1214.
62. Pocard, M., Chevillard, S., Villaudy, J., Poupon, M.F., Dutrillaux, B., and Remvikos, Y. (1996). Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation. Oncogene 12, 875-882.
63. Rhim, J.S., Jin, S., Jung, M., Thraves, P.J., Kuettel, M.R., Webber, M.M., and Hukku, B. (1997). Malignant transformation of human prostate epithelial cells by N-nitroso-N-methylurea. Cancer Res. 57, 576-580.
64. Ryan, K.M. and Vousden, K.H. (1998). Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol. Cell. Biol. 18, 3692-3698.
65. Scian, M.J., Stagliano, K.E., Deb, D., Ellis, M.A., Carchman, E.H., Das, A., Valerie, K., Deb, S.P., and Deb, S. (2004a). Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene 23, 4430-4443.
66. Scian, M.J., Stagliano, K.E., Ellis, M.A., Hassan, S., Bowman, M., Miles, M.F., Deb, S.P., and Deb, S. (2004b). Modulation of gene expression by tumor-derived p53 mutants. Cancer Res. 64, 7447-7454.
67. Shiraishi, K., Kato, S., Han, S.Y., Liu, W., Otsuka, K., Sakayori, M., Ishida, T., Takeda, M., Kanamaru, R., Ohuchi, N., et al. (2004). Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J. Biol. Chem. 279, 348-355.
68. Sigal, A. and Rotter, V. (2000). Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60, 6788-6793.
69. Soong, R., Knowles, S., Williams, K.E., Hammond, I.G., Wysocki, S.J., and Iacopetta, B.J. (1996). Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br. J. Cancer 74, 562-567.
70. Stenmark-Askmalm, M., Stal, O., Sullivan, S., Ferraud, L., Sun, X.F., Carstensen, J., and Nordenskjold, B. (1994). Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur. J. Cancer 30A, 175-180.
71. Sun, X.F., Carstensen, J.M., Zhang, H., Stal, O., Wingren, S., Hatschek, T., and Nordenskjold, B. (1992). Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340, 1369-1373.
72. Tavoloni, N. and Inoue, H. (1997). Cellular aging is a critical determinant of primary cell resistance to v-src transformation. J. Virol. 71, 237-247.
73. Tsang, W.P., Ho, F.Y., Fung, K.P., Kong, S.K., and Kwok, T.T. (2005). p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int. J. Cancer 114, 331-336.
74. Unger, T., Mietz, J.A., Scheffner, M., Yee, C.L., and Howley, P.M. (1993). Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol. Cell. Biol. 13, 5186-5194.
75. Vogelstein, B. (1990). A deadly inheritance. Nature 348, 681-682.
76. Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., and Fenaux, P. (1994). p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84, 3148-3157.
77. Williams, A.C., Miller, J.C., Collard, T.J., Bracey, T.S., Cosulich, S., and Paraskeva, C. (1995). Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation. Oncogene 11, 141-149.
78. Woloschak, M., Yu, A., and Xiao, J. (1996). Molecular and cellular responses to DNA damage in a murine pituitary adenoma cell line. Mol. Cell. Endocrinol. 119, 61-68.
79. Xiong, Y., Hannon, G.J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. (1993). p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704.
80. Zerrhan, J., Deppert, W., Weideman, D., Patschinsky, T., Richards, F., and Milner, J. (1992). Correlation between the conformational phenotype of p53 and its subcellular location. Oncogene 7, 1371-1381.